Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco

About this trial

The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.

Eligibility criteria

Qualifiers

Kellgren-Lawrence (KL) Grade 1-3 knee osteoarthritis

Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee

Will be able to attend and perform physical therapy

Disqualifiers

Received injection therapy for knee osteoarthritis in the past 6 months

Have severe arthritis diagnosed in ≥1 major joint by radiology criteria

History of septic arthritis

Underwent knee surgery for osteoarthritis or osteochondral defects within 1 year before randomization (e.g., autograft or allograft surgery)

Trial design

Treatments tested in this trial

  • Platelet Rich Plasma
  • Emcyte PurePRP Supraphysiologic Concentrating System
  • APEX Biologix XCELL PRP System

Treatment groups

20 Participants
are divided into 2 treatment groups